Global Targeted DNA RNA Sequencing Market 2026 – 2035

The market size of the global Targeted DNA RNA Sequencing will be estimated at USD 8.6 billion in 2025 and is expected to grow to between USD 10.2 billion in 2026 and about USD 46.9 billion by 2035 with a current CAGR of 18.5% during the period of 2026 to 2035. Targeted DNA and RNA sequencing functions as a next-generation sequencing (NGS) method that enables researchers to examine specific genetic elements through focused studies instead of conducting whole-genome or whole-transcriptome analyses.

The method achieves high sequencing depth together with better sensitivity and quicker result delivery through targeted enrichment methods that use both amplicon-based and hybrid-capture panels. The system detects DNA variants between single nucleotide variations and insertions and deletions and copy number alterations, and it detects RNA features, which include gene fusions and splice variants and expression changes. The system achieves widespread use as a diagnostic tool in clinical settings and in precision oncology and infectious disease testing and liquid biopsy and translational research, which requires specific and useful genomic data.

The targeted DNA and RNA sequencing market exists because precision medicine and personalized medicine adoption increases in oncology through targeted panels, which medical professionals use to find genetic mutations and gene fusions that determine appropriate treatments and their effectiveness. The global increase in cancer cases and genetic disorders, together with the rising need for molecular diagnostics, drives healthcare facilities to implement targeted sequencing as their standard clinical procedure. Small and mid-sized laboratories face challenges because they must spend large amounts of money to acquire sequencing platforms and automation systems and advanced bioinformatics infrastructure, which creates a substantial barrier for these laboratories in developing countries.

Market Highlight

• In 2025, North America will dominate the global market with an estimated market share of 44%.

• Asia Pacific is growing at the highest CAGR of 18.9% over the analysis period.

• By workflow, the sequencing segment dominated the market in 2024 because it secured 56.30% of the market share.

• By end use, the hospitals & clinics segment captures the largest market share of over 45% in 2025.

Significant Growth Factors

The Targeted DNA RNA Sequencing market trends present significant growth opportunities due to several factors:

• Increasing cancer incidence and genomic diagnostic demand: The targeted DNA and RNA sequencing market experiences expansion because two factors drive the market, which are rising cancer rates and increased need for genomic diagnostics. The global cancer burden has grown so much that it now creates urgent requirements for precise early detection methods, which need personalized diagnostic solutions. Targeted sequencing enables precise identification of actionable genetic mutations, gene fusions, and expression profiles, which are essential for cancer diagnosis and prognosis and therapy selection. The adoption of targeted DNA and RNA sequencing by hospitals and diagnostic laboratories and research institutions helps oncology care because these facilities use the technology to conduct companion diagnostics and treatment monitoring and minimal residual disease detection, which benefits market growth. For instance, according to John Wiley & Sons, Inc., approximately 2,114,850 new cancer cases and 626,140 cancer deaths are expected to occur in the United States in 2026.

• Regulatory & reimbursement progress for clinically validated NGS panels: The targeted DNA and RNA sequencing market experiences growth through two main drivers, such as regulatory progress and reimbursement progress for clinically validated NGS panels, which receive testing approval through NGS panels. The establishment of clearer regulatory frameworks together with increasing approval rates for validated targeted NGS assays has raised clinical confidence and resulted in their adoption as standard diagnostic procedures. The reimbursement coverage expansion by public and private payers for approved genomic tests has made testing more affordable and accessible to patients. This trend has led to increased test adoption by hospitals and diagnostic laboratories. The rising acceptance of regulations and the backing of payers for targeted DNA and RNA sequencing technologies lead to increased clinical usage of these technologies, which results in major market growth.

What are the Major Advances Changing the Targeted DNA RNA Sequencing Market Today?

• Rise of liquid biopsy–optimized targeted panels: Liquid biopsy-optimized targeted panels have created an important advancement within the targeted DNA and RNA sequencing market because the technology enables non-invasive genomic profiling that achieves exceptional accuracy by analyzing circulating tumor DNA (ctDNA) and RNA from blood samples. The panels function as detection systems that identify low-frequency mutations and gene fusions and minimal residual disease (MRD) using high-accuracy methods, which eliminate the obstacles traditional tissue biopsies create through their need for invasive procedures, their limited ability to collect samples, and their inability to represent different tumor types. The adoption of their clinical applications for early cancer detection and treatment selection and therapy monitoring and disease recurrence surveillance is increasing across oncology diagnostics, which results in market growth while establishing liquid biopsy as a primary driver of expansion for targeted sequencing technologies.

• Advances in bioinformatics and AI-driven data analysis: The targeted DNA and RNA sequencing market experiences transformation through bioinformatics and AI-based data analysis developments, which improve sequencing results through faster and more precise and clinically applicable methods. Modern bioinformatics platforms and AI-enabled algorithms streamline complex workflows such as read alignment, variant calling, annotation, and interpretation, while improving the detection of low-frequency variants and clinically relevant biomarkers. The technologies enable faster analysis processes, which decrease the need for expert staff and provide standardized reproducibility and real-time clinical decision support. Scientists use bioinformatics and AI technologies to advance targeted DNA and RNA sequencing into a more affordable and efficient solution, which doctors can use during standard clinical testing and personalized medical treatment.

Category Wise Insights

By Workflow

Why Sequencing Lead the Market?

The sequencing segment dominated the market in 2024 because it secured 56.30% of the market share. The dominant position of this element proves its essential function throughout all operational phases. The sequencing segment establishes the particular nucleotide sequence of targeted DNA or RNA which serves as the foundation for subsequent analyses that drive market expansion.

The data analysis segment is expected to grow at the fastest CAGR over the projected period. The expansion of precision medicine and genomic diagnostics shows substantial growth because these technologies are gaining increasing usage in cancer treatment. Rising cancer rates, together with the need for precise molecular profiling solutions, drive healthcare facilities and testing laboratories and research organizations to implement targeted sequencing panels, which they use for therapy selection, disease monitoring, and companion diagnostics. The increasing adoption of liquid biopsy-based targeted panels, which provide non-invasive testing and multiple monitoring capabilities, results in revenue growth through higher testing volume. The combination of falling sequencing costs and the emergence of portable benchtop sequencers, together with advancements in panel development and automated systems and bioinformatics technology, creates better access to targeted DNA and RNA sequencing for medical facilities.

By End Use

Why Hospitals & Clinics Dominates the Targeted DNA RNA Sequencing Market?

The hospitals & clinics segment captures the largest market share of over 45% in 2025. The segment growth is due to the increasing integration of genomic testing into routine clinical care, which especially benefits oncology and cardiology and rare disease diagnostics. Hospitals and clinics are adopting targeted sequencing panels to support precision medicine because these tests deliver fast results at low costs while identifying actionable genetic mutations and gene fusions, which healthcare providers use to make treatment choices. Revenue growth is further driven by the rising number of cancer patients who increasingly use liquid biopsy-based targeted assays for non-invasive monitoring, together with the availability of compact benchtop sequencers that enable in-house testing with shorter turnaround times. The clinical adoption of NGS panels has increased because improved regulatory approvals together with better reimbursement policies now support financially accessible NGS panels for clinical use. Enhanced automation and bioinformatics solutions are allowing hospitals and clinics to increase their testing capacity, which leads to higher revenue growth in this end-user segment.

The pharma & biotech entities segment is expected to grow at the highest rate over the projected period. The growth is driven by the expanding use of genomic profiling in drug discovery and biomarker identification and companion diagnostics development. Pharma and biotech companies increasingly use targeted sequencing panels because these assays provide high sensitivity and reproducibility and cost-effective results, which will help them identify specific patient groups and confirm treatment targets and create their clinical trials. Revenue growth is driven by three factors, which include rising precision oncology pipelines and increased requirements for RNA-based fusion and expression analysis and the growing use of liquid biopsy targeted assays in treatment monitoring and clinical trial assessments. The adoption of targeted DNA and RNA sequencing in the pharmaceutical and biotechnology industries will continue to expand because companies maintain their research and development expenditures, build partnerships with diagnostic companies, and regulatory bodies increasingly accept companion diagnostics.

Report Scope

Regional Analysis

How Big is the North America Targeted DNA RNA Sequencing Market Size?

Its market size, in terms of North America Targeted DNA RNA Sequencing, is projected to be USD 3.8 billion in 2025 with a growth of about USD 15.1 billion in 2035 with a CAGR of 14.8% between 2026 and 2035.

Why did North America Dominate the Targeted DNA RNA Sequencing Market in 2025?

In 2025, North America will dominate the global market with an estimated market share of 44%. The region develops because it has advanced healthcare systems, and its medical facilities started using precision medicine and genomic diagnostic solutions. High cancer prevalence, widespread use of molecular profiling in oncology, and strong demand for companion diagnostics are driving routine clinical adoption across hospitals, diagnostic laboratories, and cancer centers. The business experiences revenue growth because hospitals and laboratories and cancer centers quickly adopt liquid biopsy-based targeted sequencing panels, which provide non-invasive testing and disease tracking. The market revenue increases because top sequencing technology companies and continuous pharmaceutical and biotechnology research development and targeted sequencing use in drug development and clinical trials create a better environment for business expansion. North America emerges as a major driver of worldwide targeted DNA and RNA sequencing market revenue growth because advanced bioinformatics systems, together with better reimbursement for certified NGS panels and advantageous regulatory systems, drive market expansion.

U.S. Targeted DNA RNA Sequencing Market Trends

In the North American region, the US leads the industry expansion over the projected period. The country leads through its precision medicine expertise, its oncology research capabilities and its advanced clinical diagnostic systems which drive the growth of its medical field. Hospitals and cancer centers and reference laboratories adopt genomic profiling because of the high cancer rates and its use in guiding treatment selection and companion diagnostics. The rapid growth of liquid biopsy-based targeted sequencing panels which provide non-invasive testing and treatment monitoring and minimal residual disease detection capabilities drives revenue growth. The growing need for targeted DNA and RNA sequencing solutions results from strong pharmaceutical and biotechnology research and development activities, the extensive clinical trial pipelines and the close partnerships between diagnostic companies and drug developers. The U.S. market experiences sustained revenue growth because of favorable regulatory oversight and increasing FDA approvals and enhanced reimbursement policies for clinically validated NGS assays together with ongoing developments in sequencing platforms and bioinformatics. Furthermore, the growing product launch is expected to offer a lucrative opportunity for the industry's growth. For instance, in November 2025, Mission Bio, which specializes in single-cell multi-omics solutions for precision medicine, introduced its Tapestri® Single-Cell Targeted DNA + RNA Assay as the first commercial platform that enables simultaneous measurement of genotypic and transcriptional data within individual cells. The assay empowers oncology and translational researchers to directly link mutations to their functional consequences, which allows them to discover the mechanisms that drive resistance and relapse and therapeutic response, thus advancing precision medicine through the development of more effective therapeutic innovations.

Why is Asia Pacific Experiencing the Fastest Growth in the Targeted DNA RNA Sequencing Market?

Asia Pacific is growing at the highest CAGR of 18.9% over the analysis period. The regional growth is driven by the expanding adoption of genomic diagnostics and precision medicine across both developed and emerging economies. The demand for targeted sequencing in hospitals and diagnostic laboratories is increasing because cancer cases are rising while testing facilities experience a large patient load and medical professionals become more knowledgeable about using molecular profiling to identify diseases early and choose appropriate therapies. The revenue growth receives additional support from government efforts that develop genomic research facilities and through increased funding for biotechnology and pharmaceutical research and development and the growth of domestic sequencing centers which decrease testing expenses and improve testing efficiency. The medical community is starting to use liquid biopsy-based targeted panels because of improved healthcare access and better regulatory systems and reimbursement standards. The combination of these factors establishes Asia Pacific as one of the fastest-growing regions in the worldwide market for targeted DNA and RNA sequencing.

China Targeted DNA RNA Sequencing Market Trends

China is growing at the fastest rate over the projected period. The country experiences economic development because its population continues to increase, which creates a strong need for advanced medical services. The government policies make local industries focus on developing targeted sequencing systems which will improve access to those systems for research and diagnostic purposes.

Why is Europe is growing at a significant rate in the Targeted DNA RNA Sequencing Market?

Europe holds the substantial market share over the projected period. The growth of the industry comes from two factors governmental support of genomics research and increased focus on personalized medicine programs. The European market supports targeted sequencing technology expansion because of these factors which create a favorable operating environment for market players and researchers.

UK Targeted DNA RNA Sequencing Market Trends

The UK holds the dominant position in the Europe market. The UK provides complete training programs in genomics which enable research facilities to implement genomic techniques for their medical studies. The 100,000 Genomes Project and genomic infrastructure development programs which operate through government-related schemes, enable healthcare organizations in the UK to implement targeted sequencing technology.

Why is the Middle East & Africa Region is growing rapidly in the Targeted DNA RNA Sequencing?

The MEA region is growing at a steady rate over the projected period. The growing cancer rates together with government genomics initiatives and improved ties with international biotech and diagnostic firms create an increased need for targeted sequencing systems which hospitals research facilities and clinical labs require throughout the region.

UAE Targeted DNA RNA Sequencing Market Trends

The UAE is growing at the highest CAGR during the forecast period. The nation's strategic commitment to advanced medical research and precise medical treatment and genomic studies drives this development. The growing number of cancer cases together with the increasing need for precise molecular testing in early diagnosis has created a demand for hospitals and specialty clinics to use targeted sequencing panels in their oncology and hereditary disease testing programs.

Top Players in the Targeted DNA RNA Sequencing Market and Their Offerings

• Illumina

• F. Hoffman-La Roche Ltd.

• QIAGEN

• Thermo Fisher Scientific Inc.

• Bio-Rad Laboratories Inc.

• Oxford Nanopore Technologies

• PierianDx

• Genomatix GmbH

• DNASTAR Inc.

• Perkin Elmer Inc.

• Others

Key Developments

Targeted DNA RNA Sequencing market has experienced considerable changes in the last two years as the market players are trying to diversify their technological aspects and develop product portfolios using strategic approaches.

• In October 2025, Roche introduced its upgraded sequencing by expansion SBX system at the American Society of Human Genetics ASHG 2025 Annual Meeting which took place in Boston USA. The sequencing community has already begun to recognize SBX through its initial evaluations because it delivers rapid results with adaptable features and extended reading capabilities which open up new research opportunities. (https://www.roche.com/media/releases/med-cor-2025-10-16)

• In July 2025, QIAGEN is proud to announce the introduction of the QIAseq xHYB Long Read Panel, a set of solutions for target enrichment with access to long-read sequencing in genomic areas. (https://corporate.qiagen.com/English/newsroom/press-releases/press-release-details/2025/QIAGEN-Expands-NGS-Portfolio-with-Launch-of-QIAseq-xHYB-Long-Read-Panels/default.aspx)

These strategic measures have enabled the companies to reinforce their competitive positions, increase the product line, boost their technological competencies and also seize growth opportunities in the fast-growing Targeted DNA RNA Sequencing market.

The Targeted DNA RNA Sequencing Market is segmented as follows:

By Technology

• NGS

  • Method

    • Exome Sequencing

    • Enrichment Sequencing

    • Amplicon Sequencing

    • Others

  • Application

    • Cancer Gene Sequencing

    • Inherited Disease Screening

    • Drug Development

    • Forensic Genomics

    • 16S ribosomal RNA (rRNA) sequencing

• Others

By Workflow

• Data Analysis

• Pre-sequencing

• Sequencing

By Application

• Drug Discovery

• Human Biomedical Research

• Plant & Animal Sciences

• Others

By Type

• DNA Based Targeted Sequencing

• RNA Based Targeted Sequencing

By End Use

• Academic Research

• Pharma & Biotech Entities

• Hospitals & Clinics

• Others

Regional Coverage:

North America

• U.S.

• Canada

• Mexico

• Rest of North America 

Europe

• Germany

• France

• U.K.

• Russia

• Italy

• Spain

• Netherlands

• Rest of Europe

Asia Pacific

• China

• Japan

• India

• New Zealand

• Australia

• South Korea

• Taiwan

• Rest of Asia Pacific 

The Middle East & Africa

• Saudi Arabia

• UAE

• Egypt

• Kuwait

• South Africa

• Rest of the Middle East & Africa

Latin America

• Brazil

• Argentina

• Rest of Latin America